Evaluation of On-Couch CBCT Image Quality

Launched by VARIAN, A SIEMENS HEALTHINEERS COMPANY · Aug 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technology called HyperSight, which is used to take detailed pictures of patients undergoing radiation treatment for various types of cancer, including cancers of the head, neck, lungs, liver, pancreas, prostate, and more. The goal is to understand how well this technology works and how useful it is for doctors during treatment. The trial is currently recruiting participants who are 18 years or older and have been diagnosed with cancer that requires radiation therapy using a Varian TrueBeam system.

Eligible participants must have a plan to receive a specific amount of radiation—at least 20 Gy delivered over at least 5 days. If you join the study, you’ll be asked to provide informed consent, meaning you’ll agree to participate after understanding the study’s details. It’s important to note that pregnant individuals or those planning to become pregnant during treatment cannot participate. This trial aims to improve the care and treatment options for cancer patients, so your involvement could help advance cancer treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient age is ≥ 18 years old.
• • Patient has a diagnosis of primary or metastatic cancer, including but not limited to tumors arising from or involving the head/neck, lungs, liver, pancreas, prostate, urinary bladder, rectum, cervix or uterus.
• • A previous (standard-of-care) decision was made to treat the patient with radiation therapy using a Varian TrueBeam treatment system.
• • A previous (standard-of-care) decision was made to treat the patient with a radiation dose of at least 20 Gy in at least 5 fractions, one fraction per day on consecutive days, Monday to Friday.
• • Patient is willing and able to provide informed consent to participate in the study.
• Exclusion Criteria:
• • Patient is pregnant or has plans for pregnancy during the period of treatment.
• • Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response").